Keyphrases
Adverse Events
14%
Age Groups
9%
Anticonvulsant
11%
Antiepileptic Drugs
90%
Antiseizure Medication
12%
Carbamazepine
51%
Clinical Trials
15%
Co-medication
9%
Coefficient of Variation
10%
Drug Concentration
10%
Drug Interactions
11%
Drug Use
13%
Elderly nursing Home Residents
18%
Elderly Patients
20%
Epilepsy
63%
Epilepsy in Elderly
19%
Epilepsy Patients
11%
Epilepsy Treatment
20%
Epileptic Patients
9%
Epileptic Seizure
9%
Felbamate
32%
Fosphenytoin
8%
Gabapentin
15%
Intractable Epilepsy
12%
Lamotrigine
16%
Levetiracetam
31%
New Antiepileptic Drugs
15%
Nursing Home Residents
10%
Nursing Homes
16%
Older Adults
13%
Partial Seizures
25%
Patients with Epilepsy
38%
Pharmacokinetics
41%
Phenobarbital
20%
Phenytoin
97%
Placebo
21%
Plasma Concentration
10%
Refractory Epilepsy
9%
Seizure
69%
Seizure Frequency
11%
Seizure Type
9%
Serum Concentration
12%
Status Epilepticus
28%
Steady State
13%
Tiagabine
13%
Topiramate
20%
United States
9%
Valproate
17%
Valproic Acid
15%
Zonisamide
23%
Pharmacology, Toxicology and Pharmaceutical Science
Add on Therapy
7%
Adverse Event
16%
Anticonvulsive Agent
100%
Bioavailability
12%
Cannabidiol
6%
Carbamazepine
44%
Cerebrovascular Accident
6%
Clinical Study
5%
Clinical Trial
12%
Clonazepam
5%
Complex Partial Seizure
7%
Diazepam
6%
Diseases
23%
Dose Concentration
5%
Drug Concentration
9%
Drug Interaction
14%
Drug Resistant Epilepsy
6%
Elimination
5%
Epileptic State
25%
Felbamate
29%
Focal Epilepsy
25%
Fosphenytoin Sodium
11%
Gabapentin
15%
Intractable Epilepsy
10%
Lamictal
20%
Levetiracetam
26%
Lorazepam
8%
Normal Human
8%
Oral Contraceptive
5%
Oxcarbazepine
6%
Pharmacokinetics
66%
Pharmacotherapy
7%
Phenobarbital
21%
Phenytoin
90%
Placebo
31%
Prevalence
16%
Protein Binding
5%
Side Effect
10%
Sodium Valproate
33%
Tiagabine
13%
Tolerability
9%
Topiramate
18%
Zonisamide
23%